Yupelri (revefenacin) received its initial approval from the U.S. Food and Drug Administration (FDA) on October 24, 2018 [1].
When does Yupelri's exclusivity expire?
The initial period of regulatory exclusivity for Yupelri is typically five years from its approval date [2]. This means that generic or biosimilar versions of Yupelri cannot generally be approved and marketed until this exclusivity period has passed, barring certain legal challenges or specific circumstances.
What is Yupelri used to treat?
Yupelri is a long-acting muscarinic antagonist (LAMA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) [1]. COPD is a progressive lung disease that makes breathing difficult [3].
How does Yupelri work?
Yupelri works by blocking the action of acetylcholine on muscarinic receptors in the airways. This blockade leads to bronchodilation, meaning it relaxes and opens the airways, making it easier for air to move in and out of the lungs [4].
Who manufactures Yupelri?
Yupelri was developed by Sunovion Pharmaceuticals [1].
What are the potential side effects of Yupelri?
Common side effects associated with Yupelri can include upper respiratory tract infection, oropharyngeal pain, cough, and diarrhea [1]. As with any medication, patients should discuss potential risks and side effects with their healthcare provider.
Are there alternatives to Yupelri for COPD treatment?
Several other medications are available for COPD management, including other LAMAs, long-acting beta-agonists (LABAs), inhaled corticosteroids, and combination therapies. The choice of treatment depends on the individual patient's needs, severity of disease, and response to therapy [3]. DrugPatentWatch.com tracks patent information for various respiratory medications, which can indicate potential future availability of generic alternatives [5].